



Universiteit
Leiden
The Netherlands

Corrigendum to: denosumab reduces lesional fluoride skeletal burden on Na[18F]F PET-CT in patients with fibrous dysplasia/McCune-Albright syndrome (vol 106, pg e2980, 2021)

Bruggen, W. van der; Vriens, D.; Meier, M.E.; Smit, F.; Winter, E.M.; Geus-Oei, L.F. de; Appelman-Dijkstra, N.M.

Citation

Bruggen, W. van der, Vriens, D., Meier, M. E., Smit, F., Winter, E. M., Geus-Oei, L. F. de, & Appelman-Dijkstra, N. M. (2022). Corrigendum to: denosumab reduces lesional fluoride skeletal burden on Na[18F]F PET-CT in patients with fibrous dysplasia/McCune-Albright syndrome (vol 106, pg e2980, 2021). *The Journal Of Clinical Endocrinology & Metabolism*, 107(5), E2218-E2218. doi:10.1210/clinem/dgab785

Version: Publisher's Version
License: [Creative Commons CC BY-NC-ND 4.0 license](https://creativecommons.org/licenses/by-nc-nd/4.0/)
Downloaded from: <https://hdl.handle.net/1887/3735980>

Note: To cite this publication please use the final published version (if applicable).

Corrigendum

Corrigendum to: Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune–Albright Syndrome

In the above-named article by van der Bruggen W, Vriens D, Meier ME, Smit F, Winter EM, de Geus-Oei LF, and Appelman-Dijkstra NM (*J Clin Endo Metab.* 2021; 106(8): e2980–e2994; doi: 10.1210/clinem/dgab212), an error occurred in the references list of the version initially published online:

References after reference 10 were incorrectly numbered. The reference numbers have been corrected in the article online.
doi: 10.1210/clinem/dgab212